Page 2 - Strides Pharma News Today

Among smallcaps, Kaveri Seed was LIC ownership reducing by about half to 2.66% in Q3. In MOIL, LIC stake fell from 7.42% to 5.46% quarter-on-quarter, shows ACE Equity data.

Listed pharmaceuticals player Eris Lifesciences Ltd has acquired 51% stake in sterile injectables company Swiss Parenterals for Rs 637.5 crore (around $76.7 million), thus foraying ......

Bajaj Finance sold 0.88 percent stake in Strides Pharma Science and Amansa Holding bought 1.24 percent stake.

Around 11.40 lakh shares were sold, which represent a 1.24 per cent stake in the company. The shares were sold at an average price of Rs 713 per piece, taking the combined transaction value to Rs 81.30 crore.

Sharekhan is bullish on Strides Pharma Science has recommended buy rating on the stock with a target price of Rs 800 in its research report dated January 30, 2024.

Market is likely to be volatile in the event-packed week as the participants will focus on the Interim Budget, Federal Reserve interest rate decision and auto sales for January.

The promoter has raised ₹350 crore in debt from Modulus Alternatives to help with the buyout. The fund, borrowed at the promoter level, is being used to refinance the debt.

Global Ethosuximide Market Analysis (2019 - 2030)

In the largecap segment, 15 companies witnessed significant block deals which were worth Rs 5,729 crore, led by Kotak Mahindra Bank.

Gautam Shah says: “One has to be very stock specific in this market, but just ensure that you are in stocks which have high institutional interest because there is so much money coming into midcaps and smallcaps, Rs 8,000 crore every month, That will propel many of these stocks higher and they will get re-rated along the way.”